Jeffrey Triska1, Neil Maitra2, Matthew R Deshotels2, Faris Haddadin3, Dominick J Angiolillo4, Gemma Vilahur5,6, Hani Jneid7, Dan Atar8,9, Yochai Birnbaum3. 1. The Department of Medicine, Baylor College of Medicine, Houston, TX, USA. jeffrey.triska@bcm.edu. 2. The Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. The Section of Cardiology, Baylor College of Medicine, Houston, TX, USA. 4. Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA. 5. Cardiovascular Program, Research Institute Hospital de La Santa Creu I Sant Pau, IIB-Sant Pau, Barcelona, Spain. 6. CiberCV, Institute Carlos III, Madrid, Spain. 7. Department of Medicine, Section of Cardiology, University of Texas Medical Branch, Galveston, TX, USA. 8. The Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway. 9. Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
AIMS: This review summarizes the findings of preclinical studies evaluating the pleiotropic effects of ticagrelor. These include attenuation of ischemia-reperfusion injury (IRI), inflammation, adverse cardiac remodeling, and atherosclerosis. In doing so, it aims to provide novel insights into ticagrelor's mechanisms and benefits over other P2Y12 inhibitors. It also generates viable hypotheses for the results of seminal clinical trials assessing ticagrelor use in acute and chronic coronary syndromes. METHODS AND RESULTS: A comprehensive review of the preclinical literature demonstrates that ticagrelor protects against IRI in the setting of both an acute myocardial infarction (MI), and when MI occurs while on chronic treatment. Maintenance therapy with ticagrelor also likely mitigates adverse inflammation, cardiac remodeling, and atherosclerosis, while improving stem cell recruitment. These effects are probably mediated by ticagrelor's ability to increase local interstitial adenosine levels which activate downstream cardio-protective molecules. Attenuation and augmentation of these pleiotropic effects by high-dose aspirin and caffeine, and statins respectively may help explain variable outcomes in PLATO and subsequent randomized controlled trials (RCTs). CONCLUSION: Most RCTs and meta-analyses have not evaluated the pleiotropic effects of ticagrelor. We need further studies comparing cardiovascular outcomes in patients treated with ticagrelor versus other P2Y12 inhibitors that are mindful of the unique pleiotropic advantages afforded by ticagrelor, as well as possible interactions with other therapies (e.g., aspirin, statins, caffeine).
AIMS: This review summarizes the findings of preclinical studies evaluating the pleiotropic effects of ticagrelor. These include attenuation of ischemia-reperfusion injury (IRI), inflammation, adverse cardiac remodeling, and atherosclerosis. In doing so, it aims to provide novel insights into ticagrelor's mechanisms and benefits over other P2Y12 inhibitors. It also generates viable hypotheses for the results of seminal clinical trials assessing ticagrelor use in acute and chronic coronary syndromes. METHODS AND RESULTS: A comprehensive review of the preclinical literature demonstrates that ticagrelor protects against IRI in the setting of both an acute myocardial infarction (MI), and when MI occurs while on chronic treatment. Maintenance therapy with ticagrelor also likely mitigates adverse inflammation, cardiac remodeling, and atherosclerosis, while improving stem cell recruitment. These effects are probably mediated by ticagrelor's ability to increase local interstitial adenosine levels which activate downstream cardio-protective molecules. Attenuation and augmentation of these pleiotropic effects by high-dose aspirin and caffeine, and statins respectively may help explain variable outcomes in PLATO and subsequent randomized controlled trials (RCTs). CONCLUSION: Most RCTs and meta-analyses have not evaluated the pleiotropic effects of ticagrelor. We need further studies comparing cardiovascular outcomes in patients treated with ticagrelor versus other P2Y12 inhibitors that are mindful of the unique pleiotropic advantages afforded by ticagrelor, as well as possible interactions with other therapies (e.g., aspirin, statins, caffeine).
Authors: Christopher P Cannon; Robert A Harrington; Stefan James; Diego Ardissino; Richard C Becker; Håkan Emanuelsson; Steen Husted; Hugo Katus; Matyas Keltai; Nardev S Khurmi; Frederic Kontny; Basil S Lewis; Philippe Gabriel Steg; Robert F Storey; Daniel Wojdyla; Lars Wallentin Journal: Lancet Date: 2010-01-13 Impact factor: 79.321
Authors: Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Carl L Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao Journal: Catheter Cardiovasc Interv Date: 2013-01-08 Impact factor: 2.692
Authors: Ezra A Amsterdam; Nanette K Wenger; Ralph G Brindis; Donald E Casey; Theodore G Ganiats; David R Holmes; Allan S Jaffe; Hani Jneid; Rosemary F Kelly; Michael C Kontos; Glenn N Levine; Philip R Liebson; Debabrata Mukherjee; Eric D Peterson; Marc S Sabatine; Richard W Smalling; Susan J Zieman Journal: J Am Coll Cardiol Date: 2014-09-23 Impact factor: 24.094
Authors: Philippe Gabriel Steg; Stefan James; Robert A Harrington; Diego Ardissino; Richard C Becker; Christopher P Cannon; Håkan Emanuelsson; Ariel Finkelstein; Steen Husted; Hugo Katus; Jan Kilhamn; Sylvia Olofsson; Robert F Storey; W Douglas Weaver; Lars Wallentin Journal: Circulation Date: 2010-11-08 Impact factor: 29.690
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983
Authors: Jean-Philippe Collet; Holger Thiele; Emanuele Barbato; Olivier Barthélémy; Johann Bauersachs; Deepak L Bhatt; Paul Dendale; Maria Dorobantu; Thor Edvardsen; Thierry Folliguet; Chris P Gale; Martine Gilard; Alexander Jobs; Peter Jüni; Ekaterini Lambrinou; Basil S Lewis; Julinda Mehilli; Emanuele Meliga; Béla Merkely; Christian Mueller; Marco Roffi; Frans H Rutten; Dirk Sibbing; George C M Siontis Journal: Eur Heart J Date: 2021-04-07 Impact factor: 29.983
Authors: Daniel Lindholm; Christoph Varenhorst; Christopher P Cannon; Robert A Harrington; Anders Himmelmann; Juan Maya; Steen Husted; Philippe Gabriel Steg; Jan H Cornel; Robert F Storey; Susanna R Stevens; Lars Wallentin; Stefan K James Journal: Eur Heart J Date: 2014-04-11 Impact factor: 29.983